9 recruiting, 2 not yet recruiting. 6 Phase 2, 3 Phase 1, 1 Early Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Recruiting 4, Not yet recruiting 2 |
| Phase 1 | 3 | Recruiting 3 |
| Early Phase 1 | 1 | Recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
Follow Borderline Resectable Pancreatic Ductal Adenocarcinoma: new trials by email Literature Review of Borderline Resectable Pancreatic Ductal Adenocarcinoma trials Research Report on Borderline Resectable Pancreatic Ductal Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial Biospecimen Collection, Computed Tomography, Electronic Health Record Review - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Not yet recruiting | Northwestern University | 125 | 2027-02-03 | 2026-08-06 |
| Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer Samuraciclib, Computed Tomography, Endoscopic Ultrasound Biopsy - Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma | Phase 1 | Recruiting | University of Washington | 15 | 2026-10-15 | 2026-09-21 |
| DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer Biospecimen Collection, Computed Tomography, Dynamic Contrast-Enhanced Magnetic Resonance Imaging - Borderline Resectable Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 50 | 2026-10-01 | 2026-10-05 |
| Personalize (Signature Driven) Neoadjuvant Chemotherapy Trial for Patients With Resectable Borderline Pancreatic Ductal Adenocarcinoma. Nab paclitaxel / gemcitabine, mFOLFIRINOX - Borderline Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Not yet recruiting | Federation Francophone de Cancerologie Digestive | 110 | 2026-06-01 | 2026-06-11 |
| AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer Biopsy Procedure, Cisplatin, Computed Tomography - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Cholangiocarcinoma | Phase 1 | Recruiting | Jonsson Comprehensive Cancer Center | 46 | 2026-05-29 | 2026-08-20 |
| NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial Biospecimen Collection, Computed Tomography, Fluorouracil - Borderline Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 20 | 2026-03-02 | 2026-09-21 |
| Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment Genetic testing, Optional biopsy, Tissue collection - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma | Not applicable | Recruiting | British Columbia Cancer Agency | 200 | 2025-11-28 | 2026-09-16 |
| PULSAR in Systemic Therapy for Pancreatic Cancer Personalized Ultrafractionated Adaptive Radiotherapy - Locally Advanced Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Recruiting | Samsung Medical Center | 47 | 2025-11-14 | 2025-12-08 |
| Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer Biopsy, Biospecimen Collection, Cisplatin - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma | Phase 2 | Recruiting | Georgetown University | 36 | 2024-08-06 | 2026-09-30 |
| Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy Non-Interventional Study - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma | Recruiting | Emory University | 87 | 2024-08-05 | 2025-08-01 | |
| Targeted Pathway Inhibition in Patients With Pancreatic Cancer Cobimetinib, Olaparib, Onvansertib - Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | Early Phase 1 | Recruiting | OHSU Knight Cancer Institute | 90 | 2019-08-01 | 2026-09-04 |
Pancreatic Neoplasms (5) · Cholangiocarcinoma (1)
Digestive System Diseases (5) · Digestive System Neoplasms (5) · Endocrine Gland Neoplasms (5) · Endocrine System Diseases (5) · Neoplasms (5) · Neoplasms by Site (5) · Pancreatic Diseases (5) · Adenocarcinoma (1) · Carcinoma (1) · Neoplasms by Histologic Type (1) · Neoplasms, Glandular and Epithelial (1)
Gemcitabine (5) · Specimen Handling (5) · Fluorouracil (4) · Leucovorin (4) · Oxaliplatin (4) · Taxes (4) · dehydroftorafur (4) · 130-nm albumin-bound paclitaxel (3) · Albumin-Bound Paclitaxel (3) · Irinotecan (3) · Magnetic Resonance Spectroscopy (3) · 1,2-diaminocyclohexaneplatinum II citrate (2) · Biopsy (2) · Cisplatin (2) · Disulfides (2)
British Columbia Cancer Agency (1) · Emory University (1) · Federation Francophone de Cancerologie Digestive (1) · Georgetown University (1) · Jonsson Comprehensive Cancer Center (1) · Northwestern University (1) · OHSU Knight Cancer Institute (1) · Ohio State University Comprehensive Cancer Center (1) · Roswell Park Cancer Institute (1) · Samsung Medical Center (1) · University of Washington (1)
United States (8) · Canada (1) · France (1) · South Korea (1)
Andrew Coveler, MD (1) · Brett L Ecker, MD (1) · Charles D Lopez (1) · Christos Fountzilas (1) · Daniel J Renouf, MD (1) · Jeong Il Yu (1) · Lee S Rosen (1) · Mihir M Shah (1) · Mihir M. Shah, MD, MS, FACS, FSSO (1) · Shafia Rahman, MD (1)
P30CA060553 (1), P30CA138292 (1), R01CA290435 (1)